Mast Therapeutics Inc (MSTX) Downgraded to Hold at Zacks Investment Research
Mast Therapeutics Inc (NASDAQ:MSTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Mast Therapeutics Inc. is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments. The company’s lead product candidate is MST-188 for treating serious or life-threatening diseases. Mast Therapeutics, Inc., formerly known as ADVENTRX Pharmaceuticals, Inc., is based in San Diego, California. “
Several other brokerages have also commented on MSTX. Maxim Group set a $5.00 price target on Mast Therapeutics and gave the company a “buy” rating in a research note on Thursday, September 8th. Laidlaw lowered Mast Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 21st. Roth Capital reissued a “buy” rating and issued a $2.00 price objective on shares of Mast Therapeutics in a research note on Friday, July 15th. Canaccord Genuity reissued a “buy” rating and issued a $3.00 price objective on shares of Mast Therapeutics in a research note on Thursday, July 28th. Finally, Cowen and Company lowered Mast Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, September 23rd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $2.56.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/mast-therapeutics-inc-mstx-downgraded-to-hold-at-zacks-investment-research.html
Mast Therapeutics (NASDAQ:MSTX) opened at 0.095 on Wednesday. The company has a 50 day moving average price of $0.35 and a 200-day moving average price of $0.36. The firm’s market cap is $20.12 million. Mast Therapeutics has a 52-week low of $0.09 and a 52-week high of $0.71.
Mast Therapeutics (NASDAQ:MSTX) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. Equities research analysts anticipate that Mast Therapeutics will post ($0.19) EPS for the current year.
An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. raised its position in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned about 3.11% of Mast Therapeutics worth $2,818,000 at the end of the most recent reporting period.
Mast Therapeutics Company Profile
Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.